$ONCT
Oncternal Therapeutics Inc
PRICE
$1.53 βΌ-0.649%
Extented Hours
VOLUME
20,994,172
DAY RANGE
0.9467 - 1.61
52 WEEK
0.6902 - 5.88
Join Discuss about ONCT with like-minded investors
@maletone #StockTraders.NET
wow $ONCT tomorrow might be the day for the short
52 Replies 15 π 14 π₯
@maletone #StockTraders.NET
would be ncie if $ONCT could go higher might re hit it
51 Replies 10 π 10 π₯
@TraderXx #StockTraders.NET
$ONCT If I was shorting would cover and move on
110 Replies 6 π 7 π₯
@maletone #StockTraders.NET
covering some small here on $Onct but will add back on any nice pops $4.14
50 Replies 9 π 11 π₯
Key Metrics
Market Cap
40.47 M
Beta
1.46
Avg. Volume
400.47 K
Shares Outstanding
49.43 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
CEO: James Breitmeyer
Website: www.oncternal.com
HQ: 12230 El Camino Real Ste 300 San Diego, 92130-2090 California
Related News